Identifying Factors Underlying the Discontinuation of Triptans

The objective of this study is to identify reasons migraine patients stop using triptan medications for abortive headache treatment. It is hypothesized that inadequate education of the patient at the time of prescribing the triptan is positively associated with triptan discontinuation.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Migraine Behavior Brain Diseases Central Nervous System Diseases Headache Disorders Headache Disorders, Primary Health Behavior Medication Adherence Migraine Disorders Nervous System Diseases Patient Acceptance of Health Care Patient Compliance Treatment Adherence and Compliance

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University of South Florida College of Medicine, Tampa, Florida, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Triptan User Inclusion Criteria:

Episodic Migraine or Chronic Migraine
Have used a triptan medication in the prior 3 months
Have used triptan medications for at least 1 year

Triptan Discontinuation Inclusion Criteria:

Episodic Migraine or Chronic Migraine
Used any triptan medication in the last 2 years
Have not used a triptan medication in the last 6 months

Sponsors and collaborators

Lead sponsor

Mayo Clinic

Other

Collaborators

Merck Sharp & Dohme LLC

Registry information

Important dates

Study start: 2009
Primary completion: 2012
Study completion: 2012
First posted: Apr 29, 2009
Registry last updated: Mar 29, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed